Perinatal infections and brain injury: Current treatment options

Clinics in Perinatology

Volumn 29, Issue 4, 2002, Pages 799-826

  Sánchez, Pablo J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE; FOSCARNET; GANCICLOVIR; GENTAMICIN; IMMUNOGLOBULIN; MEASLES VACCINE; PENICILLIN G; POLIOMYELITIS VACCINE; PROCAINE PENICILLIN; RUBELLA VACCINE; SMALLPOX VACCINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VACCINE; VIDARABINE; ZIDOVUDINE;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BORRELIA BURGDORFERI; BRAIN INJURY; CANDIDA; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CONGENITAL INFECTION; CONGENITAL SYPHILIS; CYTOMEGALOVIRUS; ENTEROVIRUS; ESCHERICHIA COLI; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INTRAUTERINE INFECTION; LUMBAR PUNCTURE; LYME DISEASE; MEASLES; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA HOMINIS; MYCOSIS; NEUTROPENIA; NEWBORN INFECTION; PERINATAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; SMALLPOX; STREPTOCOCCUS AGALACTIAE; TOXOPLASMOSIS; TREPONEMA PALLIDUM; TUBERCULOSIS; UREAPLASMA UREALYTICUM; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; BIRTH INJURIES; BRAIN INJURIES; CEREBRAL PALSY; DEVELOPMENTAL DISABILITIES; FETAL DISEASES; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT, NEWBORN; INFECTION; PERINATAL CARE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0036950303     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-5108(02)00050-7     Document Type: Review

References (134)

1. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 1091-156.
2. Schrag SK, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000;342(1):15-20.
3. Baltimore RS, Huie SM, Meek JI, et al. Early-onset sepsis in the era of group B streptococcal prevention. Pediatr 2001;108(5):1094-8.
4. Wald ER, Bergman I, Taylor HG, et al. Long-term outcome of group B streptococcal meningitis. Pediatr 1986;77(2):217-21.
5. Edwards MS, Rench MA, Haffar AAM, et al. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr 1985;106(5):717-22.
6. Miron D. Once daily dosing of gentamicin in infants and children. Pediatr Infect Dis J 2001;20(12):1169-73.
7. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34(2):135-46.
8. McCracken Jr GH, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet 1980;1(8172):787-91.
9. McCracken Jr GH, Mize SG. A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy: Report of the neonatal meningitis cooperative group. J Pediatr 1976;89(1):66-72.
10. Unhanand M, Mustafa MM, McCracken Jr GH, et al. Gram-negative enteric bacillary meningitis: A twenty-one-year experience. J Pediatr 1993;122(1):15-21.
11. McCracken Jr GH, Mustafa MM, Ramilo O, et al. Cerebrospinal fluid interleukin 1-beta and tumor necrosis factor concentration and outcome from neonatal gram-negative enteric bacillary meningitis. Pediatr Infect Dis J 1989;8(3):155-9.
12. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: Results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319(15):964-71.
13. Schaad UB, Kaplan SL, McCracken Jr GH. Steroid therapy for bacterial meningitis. Clin Infect Dis 1995;20(3):685-90.
14. Christenson RD, Calhoun DA, Rimsza LM. A practical approach to evaluating and treating neutropenia in the neonatal intensive care unit. Clin Perinatol 2000;27(3):577-601.
15. Perlman JM, Rollins N, Sanchez PJ. Late-onset meningitis in sick very-low-birth-weight infants: Clinical and sonographic observations. Am J Dis Child 1992;146(11):1297-301.
16. Brook I. Anaerobic infections in the neonate. Adv Pediatr 1994;41:369-83.
17. Cassell GH, Waites KB, Watson HL, et al. Ureaplasma urealyticum intrauterine infection: Role in prematurity and disease in newborns. Clin Microbiol Rev 1993;6(1):69-87.
18. Wang EE, Matlow AG, Ohlsson A, et al. Ureaplasma urealyticum infections in the perinatal period. Clin Perinatol 1997;24(1):91-105.
19. Sánchez PJ. Perinatal transmission of Ureaplasma urealyticum: Current concepts based on review of the literature. Clin Infect Dis 1993;17(Suppl 1):S107-11.
20. Alfa MJ, Embree JE, Degagne P, et al. Transmission of Ureaplasma urealyticum from mothers to full and preterm infants. Pediatr Infect Dis J 1995; 14(5):341-5.
21. Sánchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum from mothers to preterm infants. Pediatr Infect Dis J 1990;9(6):398-401.
22. Sánchez P, Regan JA. Vertical transmission of Ureaplasma urealyticum in full term infants. Pediatr Infect Dis J 1988;6(9):825-8.
23. Syrogiannopoulos GA, Kapatais-Zoumbox K, Decavalas GO, et al. Ureaplasma urealyticum colonization of full term infants: Perinatal acquisition and persistence during early infancy. Pediatr Infect Dis J 1990;9(4):236-40.
24. Chua KB, Ngeow YF, Lim CT, et al. Colonization and transmission of Ureaplasma urealyticum and Mycoplasma hominis from mothers to full and preterm babies by normal vaginal delivery. Med J Malaysia 1999;54(2):242-6.
25. Chua KB, Ngeow YF, Ng KB, et al. Ureaplasma urealyticum and Mycoplasma hominis isolation from cervical secretions of pregnant women and nasopharyngeal secretions of their babies at delivery. Singapore Med J 1998;39(7):300-2.
26. Abele-Horn M, Peters J, Genzel-Boroviczeny O, et al. Vaginal Ureaplasma urealyticum colonization: Influence on pregnancy outcome and neonatal morbidity. Infection 1997; 25(5):286-91.
27. Garland S, Murton LJ. Neonatal meningitis caused by Ureaplasma urealyticum. Pediatr Infect Dis J 1987;6(9):868-70.
28. Gewitz M, Dinwiddle R, Rees L, et al. Mycoplasma hominis: A cause of neonatal meningitis. Arch Dis Child 1979;54(3):231-3.
29. Gilbert GL, Law F, Macinnes SJ, et al. Chronic Mycoplasma hominis infection complicating severe intraventricular hemorrhage in a premature neonate. Pediatr Infect Dis 1988;7(11): 817-8.
30. Heggie AD, Jacobs MR, Butler VT, et al. Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants. J Pediatr 1994;124(6):956-61.
31. Hentschel J, Abele-Horn M, Peters J. Ureaplasma urealyticum in the cerebrospinal fluid of a premature infant. Acta Paediatr Scand 1993;82(8):690-3.
32. Hjelm E, Jousell E, Linglof T, et al. Meningitis in a newborn infant caused by Mycoplasma hominis. Acta Paediatr Scand 1980;69(3):415-8.
33. Kirk N, Kovar I. Mycoplasma hominis meningitis in a preterm infant. J Infect 1987;15(1): 109-10.
34. Mardh PA. Mycoplasma hominis infection of the central nervous system in newborn infants. Sex Transm Dis 1983;10(Suppl 4):331-4.
35. McDonald JC. Mycoplasma hominis meningitis in a premature infant. Pediatr Infect Dis J 1988;7(11):795-8.
36. Neal TJ, Roe MF, Shaw NJ. Spontaneously resolving Ureaplasma urealyticum meningitis. Eur J Pediatr 1994;153(5):342-3.
37. Ollikainen J, Hiekkaniemi H, Korppi M, et al. Ureaplasma urealyticum cultured from brain tissue of preterm twins who die of intraventricular hemorrhage. Scand J Infect Dis 1993;25(4): 529-31.
38. Shaw NJ, Pratt BC, Weindling AM. Ureaplasma and Mycoplasma infections of the central nervous system in preterm infants. Lancet 1989;2:1530-1.
39. Siber GR, Alpert S, Smith DL, et al. Neonatal central nervous system infection due to Mycoplasma hominis. J Pediatr 1977;90(4):625-7.
40. Stahelin-Massik J, Levy F, Friderich P, et al. Meningitis caused by Ureaplasma urealyticum in a full term neonate. Pediatr Infect Dis J 1994;13(5):419-21.
41. Valencia GB, Banzon F, Cummings M, et al. Mycoplasma hominis and Ureaplasma urealyticum in neonates with suspected infection. Pediatr Infect Dis J 1993;12(7):571-3.
42. Waites KB, Duffy LB, Crouse DT, et al. Mycoplasmal infection of cerebrospinal fluid in newborn infants from a community hospital population. Pediatr Infect Dis J 1990;9(4):241-5.
43. Waites KB, Rudd PT, Crouse DT, et al. Chronic Ureaplasma urealyticum and Mycoplasma hominis infections of CNSs in preterm infants. Lancet 1988;2:17-21.
44. Waites KB, Crouse DT, Cassell GH. Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J 1992;II(I):23-9.
45. Waites KB, Crouse DT, Cassell GH. Therapeutic consideration for Ureaplasma urealyticum infections in neonates. Clin Infect Dis 1993;17(Suppl 1):S208-14.
46. Knausz M, Niederland T, Dosa E, et al. Meningo-encephalitis in a neonate caused by maternal Mycoplasma hominis treated successfully with chloramphenicol. J Med Microbiol 2002; 51(2):187-8.
47. Matlow A, Th'ng C, Kovach D, et al. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrob Agents Chemother 1998;42(5): 1290-2.
48. Waites KB, Sims PJ, Crouse DT, et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for Ureaplasma urealyticum infection. Pediatr Infect Dis J 1994;13(4):287-93.
49. Farrar HC, Walsh-Sukys MC, Pharmd KK, et al. Cardiac toxicity associated with intravenous erythromycin lactobionate: Two case reports and a review of the literature. Pediatr Infect Dis J 1993;12(8):688-91.
50. Crouse DT, Waites KB, Geerts MH, et al. Parenteral erythromycin is not associated with hearing loss in preterm infants. Clin Res 1991;39:832.
51. Centers for Disease Control and Prevention. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycin - Knoxville, Tennessee, 1999. Morb Mortal Wkly Rep 1999;48:1117.
52. Waites KB, Cassell GH, Canupp KC, et al. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones. Antimicrob Agents Chemother 1988;32(10):1500-2.
53. Sánchez PJ, Zeray F, Priest C, et al. Pharmacokinetic analysis of clarithromycin in very-low-birth-weight infants colonized with Ureaplasma urealyticum. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Poster Presentation (#A-110). Toronto, Canada, September 28-October 1, 1997.
54. Ingall D, Sánchez PJ. Syphilis. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001.
55. Benzick AE, Wirthwein DP, Weinberg A, et al. Pituitary gland gumma in congenital syphilis after failed maternal treatment: A case report. Pediatr 1999;104(1):e1-4.
56. Daaboul JJ, Kartchner W, Jones KL. Neonatal hypoglycemia caused by hypopituitarism in infants with congenital syphilis. J Pediatr 1993;123(6):983-5.
57. Nolt D, Saad R, Kouatli A, et al. Survival with hypopituitarism from congenital syphilis. Pediatr 2002;109(4):el-4.
58. Platou RV. Treatment of congenital syphilis with penicillin. Adv Pediatr 1949;4:39-86.
59. Michelow IC, Wendel Jr GD, Norgard MV, et al. Central nervous system infection in congenital syphilis. N Engl J Med 2002;346(23):1792-8.
60. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR 51 (No RR-6);2002:26-8.
61. Gardner T. Lyme disease. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 519-641.
62. Lampert F. Infantile multisystem inflammatory disease: Another case of a new syndrome. Eur J Pediatr 1986;144(6):593-6.
63. Markowitz LE, Steere AC, Benach JL, et al. Lyme disease during pregnancy. JAMA 1986; 255(24):3394-6.
64. Schlesinger PA, Duray PH, Burke BA, et al. Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann Intern Med 1985;103(1):67-8.
65. Kimberlin D, Powell D, Gruber W, et al and the NIAID Collaborative Antiviral Study Group. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes, and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996; 15(3):247-54.
66. Kimberlin DW, Lin C-Y, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001;108(2):223-9.
67. Kimberlin DW, Lakeman FD, Arvin AM, et al and the NIAID Collaborative Antiviral Study Group. Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J Infect Dis 1996;174(6):1162-7.
68. Whitley RJ, Nahmias AJ, Soong S-J, et al and the NIAID Collaborative Antiviral Study Group. Vidaribine therapy of neonatal herpes simplex virus infection. Pediatr 1980;66(4):495-501.
69. Whitley RJ, Yeager A, Kartus P, et al and the NIAID Collaborative Antiviral Study Group. Neonatal herpes simplex virus infection: Follow-up evaluation of vidaribine therapy. Pediatr 1983;72(6):778-85.
70. Whitley R, Arvin A, Prober C, et al and the NIAID Collaborative Antiviral Study Group. A controlled trial comparing vidaribine with acyclovir in neonatal herpes simplex virus infection. N Engl J Med 1991;324(7):444-9.
71. Whitley R, Arvin A, Prober C, et al and the NIAID Collaborative Antiviral Study Group. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N Engl J Med 1991;324(7)450-4.
72. Kimberlin DW, Lin C-Y, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108(2):230-8.
73. Englund JA, Fletcher CV, Balfour Jr HH. Acyclovir therapy in neonates. J Pediatr 1991; 119(1):129-35.
74. American Academy of Pediatrics. Herpes simplex. In: Pickering LK, editor. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th Edition. Elk Grove Village (IL): American Academy of Pediatrics; 2000, p. 309-18.
75. Gutman LT, Wilfert CM, Eppes S. Herpes simplex virus encephalitis in children: Analysis of cerebrospinal fluid and progressive neurodevelopmental deterioration. J Infect Dis 1986; 154(3):415-21.
76. Stagno S. Cytomegalovirus. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 389-424.
77. Boppana SB, Fowler KB, Vaid Y, et al. Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatr 1997;99(3):409-14.
78. Williamson WD, Demmler GJ, Percy AK, et al. Progressive hearing loss in infants with asymptomatic congenital cytomegalovirus infection. Pediatr 1992;90(6):862-5.
79. Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. NEJM 2001;344(18):1366-71.
80. Whitley RJ, Cloud G, Gruber W, et al and the NIAID Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: Results of a phase II study. J Infect Dis 1997;175(5)1080-6.
81. Kimberlin DW, Lin C-Y, Sanchez PJ, et al and the NIAID Collaborative Antiviral Study Group. Ganciclovir treatment of symptomatic congenital cytomegalovirus (CMV) infections: Results of phase III randomized trial. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000:Abstract 1942. p. 274.
82. Bergman I, Painter MJ, Wald ER, et al. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr 1987;110(5):705-9.
83. Aradottir E, Alonso EM, Shulman ST. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr Infect Dis J 2001;20(4):457-9.
84. Kearns GL, Bradley JS, Jacobs RF, et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatr Infect Dis J 2000;19(9):833-9.
85. Abzug MJ, Keyerling HL, Lee ML, et al. Neonatal enterovirus infection: Virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 1995;20(5):1201-6.
86. Johnson JM, Overall Jr JC. Intravenous immunoglobulin in disseminated neonatal echovirus 11 infection. Pediatr Infect Dis J 1989;8(4):254-6.
87. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331(18):1173-80.
88. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human deficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999; 341(6):385-93.
89. Centers for Disease Control and Prevention: 1994 Revised classification for human immunodeficiency virus infection in children less than 13 years of age: Official authorized addenda: Human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-19.
90. Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: Prospective study of 1739 cases. Lancet 1994;343(8912):1548-51.
91. Gershon AA. Chickenpox, measles, and mumps. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 683-732.
92. Townsend JJ, Baringer JR, Wolinsky JS, et al. Progressive rubella panencephalitis: Late onset after congenital rubella. N Engl J Med 1975;292(19):990-3.
93. Török TJ. Human parvovirus B19. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 779-811.
94. Barton LL, Budd SC, Morfit WS, et al. Congenital lymphocytic choriomeningitis virus infection in twins. Pediatr Infect Dis J 1993;12(11):942-6.
95. Bendel CM, Hostetter MK. Systemic candidiasis and other fungal infections in the newborn. Semin Pediatr Infect Dis 1994;5:35.
96. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: A report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996;129(1):63-71.
97. Faix RG. Candida parapsilosis meningitis in premature infant. Pediatr Infect Dis 1983; 2(6):462-4.
98. Faix RG. Systemic Candida infections in infants in intensive care nurseries. High incidence of central nervous system involvement. J Pediatr 1984;105(4):616-22.
99. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: A 10-year review. Clin Infect Dis 2000;31(2):458-63.
100. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low birth weight infants: Therapeutic toxicity. Pediatrics 1984;73(2):153-7.
101. Baley JE, Meyers C, Kliegman RM, et al. The pharmacokinetics, outcome and toxicity of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990;116(5):791-7.
102. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990;9(1):51-6.
103. Starke JR, Mason EO, Kramer WG, et al. Pharmacokinetics of amphotericin B in infants and children. J Infect Dis 1987;155(4):766-74.
104. Chesney PJ, Teets KC, Mulvihill JJ, et al. Successful treatment of Candida meningitis with amphotericin B and 5-fluorocytosine in combination. J Pediatr 1976;89(6):1017-9.
105. Montgomerie JZ, Edwards Jr JE, Guze LB. Synergism of amphotericin B and 5-fluorocytosine for Candida species. J Infect Dis 1975;132(1):82-6.
106. Gurses N, Kalayci AG. Fluconazole monotherapy for candidal meningitis in a premature infant. Clin Infect Dis 1996;23(3):645-6.
107. Driessen M, Ellis JB, Cooper PA, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: A prospective randomized trial. Pediatr Infect Dis J 1996;15(12): 1107-12.
108. Huttova M, Hartmanova I, Kralinsky K, et al. Candida fungemia in neonates treated with fluconazole: A report of forty cases, including eight with meningitis. Pediatr Infect Dis J 1998;17(11):1012-5.
109. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther 1993;54(3):269-77.
110. Bhandari V, Narang A, Kumar B, et al. Itraconazole therapy for disseminated candidiasis in very low birth weight neonate. J Pediatr Child Health 1992;28(4):323-4.
111. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17(2):146-8.
112. van den Anker JN. Treatment of neonatal Candida albicans septicemia with itraconazole. Pediatr Infect Dis J 1992;11(8):684-5.
113. Rowen JL, Correa AG, Sokol DM, et al. Invasive aspergillosis in neonates: Report of five cases and literature review. Pediatr Infect Dis J 1992;11(7):576-82.
114. Hageman J, Shulman S, Schreiber M, et al. Congenital tuberculosis: Critical appraisal of clinical findings and diagnostic procedures. Pediatr 1980;66(6):980-4.
115. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, editor. 2000 Red Book: Report of the Committee on Infectious Diseases. 25th Edition. Elk Grove Village (IL): American Academy of Pediatrics; 2000. p. 593-613.
116. Boyer KM, McAuley JB. Congenital toxoplasmosis. Semin Pediatr Infect Dis 1994;5:42.
117. Remington JS, McLeod R, Thulliez P, et al. Toxoplasmosis. In: Remington JS, Klein JO, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: WB Saunders; 2001. p. 205-346.
118. Alford Jr CA, Foft JW, Blanckenship WJ, et al. Subclinical central nervous system disease of neonates: A prospective study of infants born with increased levels of IgM. J Pediatr 1969; 75(6):1167-78.
119. Alford Jr CA, Stagno S, Reynolds DW. Congenital toxoplasmosis: Clinical, laboratory and therapeutic considerations, with special reference to subclinical disease. Bull N Y Acad Med 1974;50(2):160-81.
120. Guerina NG, Hsu H-W, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. N Engl J Med 1994;330(26):1858-63.
121. Saxon SA, Knight N, Reynolds DW, et al. Intellectual deficits in children born with subclinical congenital toxoplasmosis: A preliminary report. J Pediatr 1973;82(5):792-7.
122. Wilson CB, Remington JS, Stagno S, et al. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980;66(5):767-74.
123. Couvreur J, Desmonts G. Congenital and maternal toxoplasmosis: a review of 300 congenital cases. Dev Med Child Neurol 1962;4:519.
124. Couvreur J, Desmonts G, Toumier G, et al. Study of a homogeneous series of 210 cases of congenital toxoplasmosis in infants aged 0 to 11 months detected prospectively. Ann Pediatr 1984;31:815.
125. Diebler C, Dusser A, Dulac O. Congenital toxoplasmosis: Clinical and neuroradiologic evaluation of the cerebral lesions. Neuroradiology 1985;27(2):125-30.
126. Eichenwald HG. A study of congenital toxoplasmosis, with particular emphasis on clinical manifestations, sequelae, and therapy. In: Siim JC, editor. Human Toxoplasmosis. Copenhagen: Munksgaard; 1960. p. 41-9.
127. McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago collaborative treatment trial. Clin Infect Dis 1994;18(1):38-72.
128. Hohlfeld P, Daffos F, Thurlliez P, et al. Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989;115(5):765-9.
129. Koppe JG, Loewer-Sieger DH, DeRoever-Bonnet H. Result of 20-year follow-up of congenital toxoplasmosis. Lancet 1986;1(8475):254-6.
130. Hohlfeld P, Daffos F, Costa J-M, et al. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med 1994;331:695.
131. McGee T, Wolters C, Stein L, et al. Absence of sensorineural hearing abnormalities in treated infants with congenital toxoplasmosis. Otolaryngol Head Neck Surg 1992;106(1):75-80.
132. Roizen N, Swisher CN, Stein MA, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995;95(1):11-20.
133. McLeod R, Mack D, Foss R, et al. The Toxoplasmosis Study Group: levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Agents Chemother 1992;36(5):1040-8.
134. Ahmed A, Cerilli LA, Sanchez PJ. Congenital malaria in a preterm neonate: Case report and review of the literature. Am J Perinatol 1998;15(1):19-22.